168 related articles for article (PubMed ID: 1673381)
1. Pharmacokinetics of 4-hydroxycyclophosphamide and metabolites in the rat.
Hong PS; Srigritsanapol A; Chan KK
Drug Metab Dispos; 1991; 19(1):1-7. PubMed ID: 1673381
[TBL] [Abstract][Full Text] [Related]
2. Pharmacokinetics of N-2-chloroethylaziridine, a volatile cytotoxic metabolite of cyclophosphamide, in the rat.
Lu H; Chan KK
Cancer Chemother Pharmacol; 2006 Oct; 58(4):532-9. PubMed ID: 16470409
[TBL] [Abstract][Full Text] [Related]
3. Clinical pharmacokinetics of cyclophosphamide and metabolites with and without SR-2508.
Chan KK; Hong PS; Tutsch K; Trump DL
Cancer Res; 1994 Dec; 54(24):6421-9. PubMed ID: 7987837
[TBL] [Abstract][Full Text] [Related]
4. Half-life of oxazaphosphorines in biological fluids.
Sladek NE; Powers JF; Grage GM
Drug Metab Dispos; 1984; 12(5):553-9. PubMed ID: 6149904
[TBL] [Abstract][Full Text] [Related]
5. Plasma concentrations of 4-hydroxycyclophosphamide and phosphoramide mustard in patients repeatedly given high doses of cyclophosphamide in preparation for bone marrow transplantation.
Sladek NE; Doeden D; Powers JF; Krivit W
Cancer Treat Rep; 1984 Oct; 68(10):1247-54. PubMed ID: 6395951
[TBL] [Abstract][Full Text] [Related]
6. Identification and quantitation of alcophosphamide, a metabolite of cyclophosphamide, in the rat using chemical ionization mass spectrometry.
Hong PS; Chan KK
Biomed Environ Mass Spectrom; 1987 Apr; 14(4):167-72. PubMed ID: 2954602
[TBL] [Abstract][Full Text] [Related]
7. Nonlinear pharmacokinetics of cyclophosphamide and 4-hydroxycyclophosphamide/aldophosphamide in patients with metastatic breast cancer receiving high-dose chemotherapy followed by autologous bone marrow transplantation.
Chen TL; Kennedy MJ; Anderson LW; Kiraly SB; Black KC; Colvin OM; Grochow LB
Drug Metab Dispos; 1997 May; 25(5):544-51. PubMed ID: 9152592
[TBL] [Abstract][Full Text] [Related]
8. Enzymatic detoxification of phosphoramide mustard by soluble fractions from rat organ tissues.
Hong PS; Chan KK
Drug Metab Dispos; 1991; 19(3):568-73. PubMed ID: 1680621
[TBL] [Abstract][Full Text] [Related]
9. Accelerated decomposition of 4-hydroxycyclophosphamide by human serum albumin.
Kwon CH; Maddison K; LoCastro L; Borch RF
Cancer Res; 1987 Mar; 47(6):1505-8. PubMed ID: 3815352
[TBL] [Abstract][Full Text] [Related]
10. Binding of metabolites of cyclophosphamide to DNA in a rat liver microsomal system and in vivo in mice.
Hemminki K
Cancer Res; 1985 Sep; 45(9):4237-43. PubMed ID: 4028012
[TBL] [Abstract][Full Text] [Related]
11. Cyclophosphamide and 4-Hydroxycyclophosphamide/aldophosphamide kinetics in patients receiving high-dose cyclophosphamide chemotherapy.
Anderson LW; Chen TL; Colvin OM; Grochow LB; Collins JM; Kennedy MJ; Strong JM
Clin Cancer Res; 1996 Sep; 2(9):1481-7. PubMed ID: 9816324
[TBL] [Abstract][Full Text] [Related]
12. The determination of cyclophosphamide and its metabolites in blood plasma as stable trifluoroacetyl derivatives by electron capture chemical ionization gas chromatography/mass spectrometry.
Momerency G; Van Cauwenberghe K; Slee PH; Van Oosterom AT; De Bruijn EA
Biol Mass Spectrom; 1994 Mar; 23(3):149-58. PubMed ID: 8148406
[TBL] [Abstract][Full Text] [Related]
13. Conversion of 4-hydroperoxycyclophosphamide and 4-hydroxycyclophosphamide to phosphoramide mustard and acrolein mediated by bifunctional catalysis.
Low JE; Borch RF; Sladek NE
Cancer Res; 1982 Mar; 42(3):830-7. PubMed ID: 7059981
[TBL] [Abstract][Full Text] [Related]
14. The effect of busulphan on the pharmacokinetics of cyclophosphamide and its 4-hydroxy metabolite: time interval influence on therapeutic efficacy and therapy-related toxicity.
Hassan M; Ljungman P; Ringdén O; Hassan Z; Oberg G; Nilsson C; Békassy A; Bielenstein M; Abdel-Rehim M; Georén S; Astner L
Bone Marrow Transplant; 2000 May; 25(9):915-24. PubMed ID: 10800057
[TBL] [Abstract][Full Text] [Related]
15. Cytotoxic activity relative to 4-hydroxycyclophosphamide and phosphoramide mustard concentrations in the plasma of cyclophosphamide-treated rats.
Powers JF; Sladek NE
Cancer Res; 1983 Mar; 43(3):1101-6. PubMed ID: 6825082
[No Abstract] [Full Text] [Related]
16. Identification and pharmacokinetics of cyclophosphamide (NSC-26271) metabolites in vivo.
Voelcker G; Wagner T; Hohorst HJ
Cancer Treat Rep; 1976 Apr; 60(4):415-22. PubMed ID: 1277216
[TBL] [Abstract][Full Text] [Related]
17. The influence of interferon-alpha on the pharmacokinetics of cyclophosphamide and its 4-hydroxy metabolite in patients with multiple myeloma.
Hassan M; Nilsson C; Olsson H; Lundin J; Osterborg A
Eur J Haematol; 1999 Sep; 63(3):163-70. PubMed ID: 10485271
[TBL] [Abstract][Full Text] [Related]
18. The interaction of glutathione with 4-hydroxycyclophosphamide and phosphoramide mustard, studied by 31P nuclear magnetic resonance spectroscopy.
Dirven HA; Venekamp JC; van Ommen B; van Bladeren PJ
Chem Biol Interact; 1994 Dec; 93(3):185-96. PubMed ID: 7923439
[TBL] [Abstract][Full Text] [Related]
19. Population pharmacokinetics of cyclophosphamide and its metabolites 4-hydroxycyclophosphamide, 2-dechloroethylcyclophosphamide, and phosphoramide mustard in a high-dose combination with Thiotepa and Carboplatin.
de Jonge ME; Huitema AD; van Dam SM; Rodenhuis S; Beijnen JH
Ther Drug Monit; 2005 Dec; 27(6):756-65. PubMed ID: 16306851
[TBL] [Abstract][Full Text] [Related]
20. Blood levels of alkylating metabolites of cyclophosphamide in the mouse after iv or oral administration.
Struck RF; Alberts DS
Cancer Treat Rep; 1984 May; 68(5):765-70. PubMed ID: 6722832
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
